One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.

It’s the height of meeting season! All our most-read stories this month hailed from the news team’s on-site coverage.

Changes are afoot to meet higher caseloads amid rising demand, the survey of 6,830 cardiovascular providers suggests.

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

The national coverage determination explicitly outlines patient, clinician, and facilities criteria for qualifying procedures ...

The DCB is meant to address long-term stent-related complications and avoid adding yet another metal layer in ISR.

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

Having more-thorough workup uncovered an unexpected root cause and changed the treatment course for 76% of patients.

The device, which is delivered transapically, represents an option for very sick patients who previously have had none.

The real-world Evoque and new TRILUMINATE findings provide an “extension” from the pivotal trials, Dharam Kumbhani says.

The rate of death or HF hospitalization was not influenced by the presence of leads after accounting for comorbidity burden.